Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $7.14 million during the quarter, compared to analyst estimates of $6.81 million. Cytokinetics had a negative net margin of 308.73% and a negative return on equity of 575.21%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Cytokinetics.

6 brokers have issued twelve-month target prices for Cytokinetics' stock. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' stock price to reach $20.17 in the next twelve months. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

News headlines about CYTK stock have trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cytokinetics.

Some companies that are related to Cytokinetics include HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Zai Lab (ZLAB) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Geron (GERN), Inovio Pharmaceuticals (INO) and TG Therapeutics (TGTX).

Cytokinetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.10%), State of Alaska Department of Revenue (0.08%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of Alaska Department of Revenue and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $10.97.

Cytokinetics has a market capitalization of $643.72 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]